The evidence emerged so far would hence persuade us that, perhaps, the most reasonable approach is not a matter of whether therapeutic-intensity anticoagulation may be “good” or “bad,” “safe,” or “dangerous,” in patients with severe COVID-19 illness, but rather whether the correct answer to the original question could be… “depends.” Straightforwardly applying here, the concept of precision medicine, one would need to estimate the individual risk of developing venous thrombosis, that would then be balanced against the risk of bleeding.

Strength of Anticoagulation in Moderate to Severe COVID-19 Illness: In Medio Stat Virtus?

Lippi, Giuseppe
;
In corso di stampa

Abstract

The evidence emerged so far would hence persuade us that, perhaps, the most reasonable approach is not a matter of whether therapeutic-intensity anticoagulation may be “good” or “bad,” “safe,” or “dangerous,” in patients with severe COVID-19 illness, but rather whether the correct answer to the original question could be… “depends.” Straightforwardly applying here, the concept of precision medicine, one would need to estimate the individual risk of developing venous thrombosis, that would then be balanced against the risk of bleeding.
Anticoagulation, COVID-19, SARS-CoV-2
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: http://hdl.handle.net/11562/1073468
Citazioni
  • ???jsp.display-item.citation.pmc??? 0
  • Scopus ND
  • ???jsp.display-item.citation.isi??? ND
social impact